마커 테라퓨틱스 (MRKR)

전일 마감가:

$4.20

열려 있는:

$4.33

하루 거래량:

13,139

시가총액:

$37.57M

수익:

-

순이익/손실:

$-8.24M

주가수익비율:

-2.7051

EPS:

-1.56

순현금흐름:

$-16.44M

1주 성능:

-1.63%

1개월 성능:

-7.25%

6개월 성능:

+34.39%

1년 성능:

+210.29%

1일 변동 폭

$4.15

$4.4999

52주 변동 폭

$1.16

$9.6799

마커 테라퓨틱스 Stock (MRKR) Company Profile

명칭

Marker Therapeutics Inc

부문

Healthcare (1213)

산업

Biotechnology (699)

전화

713 400 6400

주소

3200 Southwest Freeway, Suite 2500, Houston, TX

직원

56

트위터

@MRKRTherapeutic

다음 수익 날짜

2024-05-13

최신 SEC 제출 서류

MRKR's Discussions on Twitter

마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-03-25	개시	Piper Sandler	Overweight
2021-03-19	개시	Cantor Fitzgerald	Overweight
2020-05-12	다운그레이드	Piper Sandler	Overweight → Neutral
2019-05-30	개시	ROTH Capital	Buy
2019-03-01	개시	Janney	Buy
2018-12-03	업그레이드	Piper Jaffray	Neutral → Overweight

모두보기

마커 테라퓨틱스 주식(MRKR)의 최신 뉴스

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

GlobeNewswire Inc.

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

GlobeNewswire Inc.

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

GlobeNewswire Inc.

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

GlobeNewswire Inc.

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

GlobeNewswire Inc.

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

GlobeNewswire Inc.

마커 테라퓨틱스 (MRKR) 재무 분석

마커 테라퓨틱스 (MRKR) 순이익 2024

마커 테라퓨틱스 (MRKR) 현금흐름 2024

마커 테라퓨틱스 (MRKR) 주당 순이익 2024